Cytosorbents Corp (CTSO) stock
CTSONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$5.37+0.03 (+0.56%)
Close on Nov 12, 2026Market cap $337.47MP/E –Yield –
Cytosorbents profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Cytosorbents's profit margin for the twelve months ending Jun 30, 2026 was -48.9%. For fiscal 2025 it was -22.1%, against -58.2% the year before. The highest annual figure on record is -19.1% in fiscal 2020.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -22.1% | +36.1 |
| FY2024 | Dec 31, 2024 | -58.2% | +35.9 |
| FY2023 | Dec 31, 2023 | -94.1% | +0.5 |
| FY2022 | Dec 31, 2022 | -94.6% | −37.7 |
| FY2021 | Dec 31, 2021 | -56.9% | −37.8 |
| FY2020 | Dec 31, 2020 | -19.1% | +58.1 |
| FY2019 | Dec 31, 2019 | -77.2% | −0.7 |
| FY2018 | Dec 31, 2018 | -76.5% | −20.6 |
| FY2017 | Dec 31, 2017 | -55.8% | +67.6 |
| FY2016 | Dec 31, 2016 | -123.5% | +74.3 |
| FY2015 | Dec 31, 2015 | -197.8% | +28.3 |
| FY2014 | Dec 31, 2014 | -226.1% | −33.0 |
| FY2013 | Dec 31, 2013 | -193.1% | +79.7 |
| FY2012 | Dec 31, 2012 | -272.8% | +14921.1 |
| FY2011 | Dec 31, 2011 | -15193.9% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -45.9% | −66.1 |
| Q1 FY2026 | Mar 31, 2026 | -57.9% | −40.9 |
| Q4 FY2025 | Dec 31, 2025 | -59.5% | +23.2 |
| Q3 FY2025 | Sep 30, 2025 | -33.4% | −1.3 |
| Q2 FY2025 | Jun 30, 2025 | 20.2% | +68.8 |
| Q1 FY2025 | Mar 31, 2025 | -16.9% | +50.8 |
| Q4 FY2024 | Dec 31, 2024 | -82.7% | −6.8 |
| Q3 FY2024 | Sep 30, 2024 | -32.1% | +72.2 |
| Q2 FY2024 | Jun 30, 2024 | -48.6% | +16.7 |
| Q1 FY2024 | Mar 31, 2024 | -67.7% | +9.8 |
| Q4 FY2023 | Dec 31, 2023 | -75.8% | −67.7 |
| Q3 FY2023 | Sep 30, 2023 | -104.3% | +46.1 |
| Q2 FY2023 | Jun 30, 2023 | -65.3% | +62.7 |
| Q1 FY2023 | Mar 31, 2023 | -77.5% | +25.6 |
| Q4 FY2022 | Dec 31, 2022 | -8.2% | +78.2 |
| Q3 FY2022 | Sep 30, 2022 | -150.4% | −84.8 |
| Q2 FY2022 | Jun 30, 2022 | -128.1% | −89.2 |
| Q1 FY2022 | Mar 31, 2022 | -103.2% | −63.8 |
| Q4 FY2021 | Dec 31, 2021 | -86.3% | −80.6 |
| Q3 FY2021 | Sep 30, 2021 | -65.6% | −57.7 |
| Q2 FY2021 | Jun 30, 2021 | -38.9% | −9.6 |
| Q1 FY2021 | Mar 31, 2021 | -39.3% | +0.3 |
| Q4 FY2020 | Dec 31, 2020 | -5.7% | +47.5 |
| Q3 FY2020 | Sep 30, 2020 | -8.0% | +105.0 |
| Q2 FY2020 | Jun 30, 2020 | -29.3% | +27.6 |
| Q1 FY2020 | Mar 31, 2020 | -39.7% | +54.4 |
| Q4 FY2019 | Dec 31, 2019 | -53.2% | +35.7 |
| Q3 FY2019 | Sep 30, 2019 | -113.0% | −60.6 |
| Q2 FY2019 | Jun 30, 2019 | -56.9% | +44.2 |
| Q1 FY2019 | Mar 31, 2019 | -94.1% | −33.5 |
| Q4 FY2018 | Dec 31, 2018 | -88.9% | −21.1 |
| Q3 FY2018 | Sep 30, 2018 | -52.3% | +1.4 |
| Q2 FY2018 | Jun 30, 2018 | -101.1% | −52.5 |
| Q1 FY2018 | Mar 31, 2018 | -60.6% | −11.6 |
| Q4 FY2017 | Dec 31, 2017 | -67.7% | +91.4 |
| Q3 FY2017 | Sep 30, 2017 | -53.7% | +37.0 |
| Q2 FY2017 | Jun 30, 2017 | -48.6% | – |
| Q1 FY2017 | Mar 31, 2017 | -49.0% | – |
| Q4 FY2016 | Dec 31, 2016 | -159.1% | – |
| Q3 FY2016 | Sep 30, 2016 | -90.7% | – |
See a number that looks wrong?